Lamisil information from drugs
Lamisil. St time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose. What happens if I overdose? Seek emergency medical attention if you think you have used too much of this medication. Overdose symptoms may include dizziness, stomach pain, nausea, vomiting, skin rash, or urinating more than usual. What should I avoid while taking Lamisil? Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using Lamisil. Lamisil side effects Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Some people taking Lamisil have developed severe liver damage leading to liver transplant or death. It is not clear whether Lamisil actually caused the liver damage in these patients. In most cases, the patient had a serious medical condition before taking Lamisil. Call your doctor at once if you have symptoms of liver damage, such as nausea, stomach pain, loss of appetite, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes). These events can occur whether or not you have ever had liver problems before. Stop taking Lamisil and call your doctor at once if you have a serious side effect such as: joint pain or swelling, swollen glands, patchy skin color, or a butterfly-shaped skin rash over your cheeks and nose; fever, chills, body aches, flu symptoms; changes in your vision; weight loss due to taste changes; scaly, itchy, and flaky skin rash
Lamisil ; does lamisil really work; how does lamisil work; lamisil
and retina have been reported following the use of LAMISIL® (terbinafine hydrochloride tablets) Tablets in controlled trials. The clinical significance of these changes is unknown. Transient decreases in absolute lymphocyte counts (ALC) have been observed in controlled clinical trials. In placebo-controlled trials, 8 465 LAMISIL®-treated patients (1.7%) and 3 137 placebo-treated patients (2.2%) had decreases in ALC to below 1000 mm3 on two or more occasions. The clinical significance of this observation is unknown. However, in patients with known or suspected immunodeficiency, physicians should consider monitoring complete blood counts in individuals using LAMISIL® therapy for greater than six weeks. Isolated cases of severe neutropenia have been reported. These were reversible upon discontinuation of LAMISIL®, with or without supportive therapy. If clinical signs and symptoms suggestive of secondary infection occur, a complete blood count should be obtained. If the neutrophil count is ≤ 1,000 cells mm3, LAMISIL® should be discontinued and supportive management started. Carcinogenesis, Mutagenesis, Impairment of Fertility In a 28-month oral carcinogenicity study in rats, an increase in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg kg day 2x the Maximum Recommended Human Dose (MRHD) based on AUC comparisons of the parent terbinafine ; however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were not tested. The results of a variety of in vitro (mutations in E. coli an